IPCA Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on January 13, 2026.
IPCALAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts less than Nifty Midcap 150 and 2.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
IPCA Laboratories informed exchanges about two decisions from its January 13, 2026 board meeting. First, the company will sell its entire shareholding in Bayshore Pharmaceuticals LLC, USA — a wholly owned step-down subsidiary — to Centaur Pharmaceuticals USA Inc for a lump-sum consideration of USD 400,000. Bayshore is essentially a shell company today: its generic formulations business and nine ANDAs were already sold to Unichem in September 2024, leaving it with no assets, no liabilities, and only a small bank balance of about USD 5,200. The sale is intended purely to cut the cost of maintaining a dormant US entity. Second, IPCA will update its registered office address on the MCA portal to include the district name (Mumbai), which is an administrative fix needed to file IEM applications — there is no actual address change.
This is a low-impact housekeeping transaction — Bayshore is already inactive and the USD 400,000 sale price is negligible relative to IPCA's size. Shareholders should not expect any material effect on earnings, operations, or stock price from this announcement.